Since Burzynski defeated the Food and Drug Administration in the 1990s, they were obligated to open up FDA-authorized clinical trials treating patients with Antineoplastons.

Since many of his patients at the time suffered from inoperable brain cancer, most of his Antineoplaston clinical data was in this realm, thus justifying a series of Phase II clinical trials to treat a myriad of different brain cancers. Without the obstruction of FDA red tape, The Burzynski Clinic would gladly treat anyone with most all cancer types if they were allowed to.

Many of the Phase II clinical trials are now complete, and published in the peer-reviewed literature.

Read the Whole Story